How does RSA’s approach differ from other executive search firms?

Most firms rely heavily on broad networks and generic recruitment practices. RSA has operated exclusively within the Life Sciences sector since 1981 so our networks are unparalleled. Our consultants are industry veterans who understand the technical nuances of your pipeline, allowing them to engage candidates peer-to-peer and validate their specific life science competencies.

What exactly is the “Proof of Candidate” methodology?

It is our proprietary due diligence framework. We do not present candidates based on “gut-feel” or reputation alone. Every shortlist is a comparative, data driven dossier that checks and validates the candidates alignment, execution history, and cultural fit, ensuring your Board can make an evidence-based hiring decision.

What is a typical timeline for a C-Suite or Board-level placement?

While complex searches require rigorous vetting, our global infrastructure allows us to move with urgency. Typically, the longlisting Strategic Blueprinting phase is completed within 2 weeks, with a qualified shortlist presented within 4 to 8 weeks. Final hire decisions are generally secured within 21 days of shortlisting.

Do you handle international searches?

Yes. Roughly 1/3 of our work involves a cross border/continent move. We operate across all major global life science hubs, including London, Boston, The Bay Area, Munich, Berlin, Basel, Shanghai and Singapore. Our model combines local and market intelligence with a truly borderless talent network, enabling us to source the best global talent regardless of geography.

Do you provide support for interim or fractional leadership needs?

Absolutely. Through RSA Interims we provide agile leadership solutions for critical inflection points. Whether you need a transition CEO, a turnaround CFO, or specific leadership to bridge the gap until a permanent appointment is made, we deploy proven operators rapidly to maintain your business velocity

News & Views | RSA Group

New Article · When AI meets the institution – 5 min read

Read here

New Article · 5 min read

Read here

News & Views

Home

Biotech
Biotech
Biotech
on
10 Sept 2026
by
The RSA Group
This is When Biotech Leadership Must Change...
on
29 Aug 2026
by
The RSA Group
When AI Meets the Institution
on
29 Aug 2026
by
The RSA Group
When AI stops being a tool and starts behaving like an organisation
on
29 Aug 2026
by
Nick Stephens
Discovery Without Consciousness
on
23 Aug 2026
by
Nick Stephens
Red-Light Starvation: Are We Missing Something Important from Modern Life?
Biotech
Biotech
Biotech
on
10 Sept 2026
by
The RSA Group
This is When Biotech Leadership Must Change...
on
29 Aug 2026
by
The RSA Group
When AI Meets the Institution
on
29 Aug 2026
by
The RSA Group
When AI stops being a tool and starts behaving like an organisation
on
29 Aug 2026
by
Nick Stephens
Discovery Without Consciousness
on
23 Aug 2026
by
Nick Stephens
Red-Light Starvation: Are We Missing Something Important from Modern Life?
Biotech
Biotech
Biotech
on
10 Sept 2026
by
The RSA Group
This is When Biotech Leadership Must Change...
on
29 Aug 2026
by
The RSA Group
When AI Meets the Institution
on
29 Aug 2026
by
The RSA Group
When AI stops being a tool and starts behaving like an organisation
on
29 Aug 2026
by
Nick Stephens
Discovery Without Consciousness
on
23 Aug 2026
by
Nick Stephens
Red-Light Starvation: Are We Missing Something Important from Modern Life?
Biotech
Biotech
Biotech
on
10 Sept 2026
by
The RSA Group
This is When Biotech Leadership Must Change...
on
29 Aug 2026
by
The RSA Group
When AI Meets the Institution
on
29 Aug 2026
by
The RSA Group
When AI stops being a tool and starts behaving like an organisation
on
29 Aug 2026
by
Nick Stephens
Discovery Without Consciousness
on
23 Aug 2026
by
Nick Stephens
Red-Light Starvation: Are We Missing Something Important from Modern Life?

Biotech
Biotech
Biotech
on
10 Sept 2026
by
The RSA Group
This is When Biotech Leadership Must Change...
RSA Group Executive Chairman Nick Stephens recently joined Citeline’s In Vivo Strategic Intent podcast to discuss leadership, board composition and the decisions that shape successful biotech companies.
on
29 Aug 2026
by
The RSA Group
When AI Meets the Institution
Why capable healthcare technology produces so little change — and how the people inside the system can alter the bargain.
on
29 Aug 2026
by
The RSA Group
When AI stops being a tool and starts behaving like an organisation
In 2026, a group of AI agents did something nobody had programmed them to do. They organised themselves.
on
29 Aug 2026
by
Nick Stephens
Discovery Without Consciousness
A fact-checked analysis of the 2026 OpenAI/Hugging Face agent incident and its implications for leadership, business and society.
on
23 Aug 2026
by
Nick Stephens
Red-Light Starvation: Are We Missing Something Important from Modern Life?
A summary and critical appraisal of the New Scientist cover story and the supporting peer-reviewed evidence
Biotech
Biotech
Biotech
on
10 Sept 2026
by
The RSA Group
This is When Biotech Leadership Must Change...
RSA Group Executive Chairman Nick Stephens recently joined Citeline’s In Vivo Strategic Intent podcast to discuss leadership, board composition and the decisions that shape successful biotech companies.
on
29 Aug 2026
by
The RSA Group
When AI Meets the Institution
Why capable healthcare technology produces so little change — and how the people inside the system can alter the bargain.
on
29 Aug 2026
by
The RSA Group
When AI stops being a tool and starts behaving like an organisation
In 2026, a group of AI agents did something nobody had programmed them to do. They organised themselves.
on
29 Aug 2026
by
Nick Stephens
Discovery Without Consciousness
A fact-checked analysis of the 2026 OpenAI/Hugging Face agent incident and its implications for leadership, business and society.
on
23 Aug 2026
by
Nick Stephens
Red-Light Starvation: Are We Missing Something Important from Modern Life?
A summary and critical appraisal of the New Scientist cover story and the supporting peer-reviewed evidence
Biotech
Biotech
Biotech
on
10 Sept 2026
by
The RSA Group
This is When Biotech Leadership Must Change...
RSA Group Executive Chairman Nick Stephens recently joined Citeline’s In Vivo Strategic Intent podcast to discuss leadership, board composition and the decisions that shape successful biotech companies.
on
29 Aug 2026
by
The RSA Group
When AI Meets the Institution
Why capable healthcare technology produces so little change — and how the people inside the system can alter the bargain.
on
29 Aug 2026
by
The RSA Group
When AI stops being a tool and starts behaving like an organisation
In 2026, a group of AI agents did something nobody had programmed them to do. They organised themselves.
on
29 Aug 2026
by
Nick Stephens
Discovery Without Consciousness
A fact-checked analysis of the 2026 OpenAI/Hugging Face agent incident and its implications for leadership, business and society.
on
23 Aug 2026
by
Nick Stephens
Red-Light Starvation: Are We Missing Something Important from Modern Life?
A summary and critical appraisal of the New Scientist cover story and the supporting peer-reviewed evidence
Biotech
Biotech
Biotech
on
10 Sept 2026
by
The RSA Group
This is When Biotech Leadership Must Change...
RSA Group Executive Chairman Nick Stephens recently joined Citeline’s In Vivo Strategic Intent podcast to discuss leadership, board composition and the decisions that shape successful biotech companies.
on
29 Aug 2026
by
The RSA Group
When AI Meets the Institution
Why capable healthcare technology produces so little change — and how the people inside the system can alter the bargain.
on
29 Aug 2026
by
The RSA Group
When AI stops being a tool and starts behaving like an organisation
In 2026, a group of AI agents did something nobody had programmed them to do. They organised themselves.
on
29 Aug 2026
by
Nick Stephens
Discovery Without Consciousness
A fact-checked analysis of the 2026 OpenAI/Hugging Face agent incident and its implications for leadership, business and society.
on
23 Aug 2026
by
Nick Stephens
Red-Light Starvation: Are We Missing Something Important from Modern Life?
A summary and critical appraisal of the New Scientist cover story and the supporting peer-reviewed evidence

Red-Light Starvation: Are We Missing Something Important from Modern Life?

23 Aug 2026

Nick Stephens

The RSA Group Appoints Andy Theodorou as Partner

7 Jul 2026

The RSA Group

Universal mRNA Influenza Vaccines: Moving into Phase III Registration Trials

20 May 2026

Stephen Paul

Red-Light Starvation: Are We Missing Something Important from Modern Life?

23 Aug 2026

Nick Stephens

The RSA Group Appoints Andy Theodorou as Partner

7 Jul 2026

The RSA Group

Universal mRNA Influenza Vaccines: Moving into Phase III Registration Trials

20 May 2026

Stephen Paul

Data-led clinical trial image representing artificial intelligence used to stratify patients for more efficient enrolment.

AI in Patient Stratification: Optimising Clinical Trial Enrolment

18 Mar 2026

Kristian Jürgensen

Industry Developments

Biotech

Stephen Paul

20 May 2026

Universal mRNA Influenza Vaccines: Moving into Phase III Registration Trials

Universal seasonal flu vaccines are entering late-stage trials. Discover the regulatory affairs leaders needed to navigate these international registration programmes.

Biotech

Stephen Paul

20 May 2026

Universal mRNA Influenza Vaccines: Moving into Phase III Registration Trials

Universal seasonal flu vaccines are entering late-stage trials. Discover the regulatory affairs leaders needed to navigate these international registration programmes.

Oncology clinical development image representing KRAS G12C inhibitor progression in pancreatic cancer.

KRAS G12C Inhibitors: Progressing Daraxonrasib in Pancreatic Cancer

29 Jan 2026

Nick Stephens

Speciality pharma launch image representing the commercialisation of Rezdiffra as the first approved MASH therapy.

Commercialising Rezdiffra: The Launch of the First Approved MASH Therapy

15 Aug 2025

Nick Stephens

Conceptual gene therapy image representing AAV treatment development for hereditary deafness.

AAV Gene Therapy for Hereditary Deafness: Clinical Progression

26 May 2025

Kristian Jürgensen

Conceptual genomic therapy image representing next-generation CRISPR base and prime editing progressing into clinical use.

Next-Generation CRISPR Gene Editing: Base and Prime Editing in the Clinic

22 Feb 2025

Kristian Jürgensen

Market Insights

The RSA Group

29 Aug 2026

When AI stops being a tool and starts behaving like an organisation

In 2026, a group of AI agents did something nobody had programmed them to do. They organised themselves.

Discovery Without Consciousness

29 Aug 2026

Nick Stephens

AI in Patient Stratification: Optimising Clinical Trial Enrolment

18 Mar 2026

Kristian Jürgensen

Diagnostics deployment image representing next-generation tuberculosis testing strategies for global health systems.

Speciality Pharma

Stephen Paul

15 Jan 2026

Next-Generation Tuberculosis Diagnostics: Global Deployment Strategies

Deploying molecular screening systems in low-resource environments requires operational directors with deep international supply chain and NGO partnerships experience.

Drug delivery platform image representing exosome-based therapeutics reaching clinical trial milestones.

Exosome-Based Drug Delivery Platforms: Clinical Trial Milestones

10 Dec 2025

Kristian Jürgensen

Speciality pharma dealmaking image representing late-stage asset licensing and value creation.

Speciality Pharma Licensing: Securing Value in Late-Stage Asset Deals

27 Nov 2025

Kristian Jürgensen

RSA Viewpoints

Biotech

The RSA Group

10 Sept 2026

This is When Biotech Leadership Must Change...

RSA Group Executive Chairman Nick Stephens recently joined Citeline’s In Vivo Strategic Intent podcast to discuss leadership, board composition and the decisions that shape successful biotech companies.

When AI Meets the Institution

29 Aug 2026

The RSA Group

Red-Light Starvation: Are We Missing Something Important from Modern Life?

23 Aug 2026

Nick Stephens

Diagnostics

Nikki Paul

27 Jan 2026

Companion Diagnostics: De-risking Clinical Trial Design

Integrating biomarkers early in drug development improves patient stratification and trial success. Sourcing diagnostic leaders who understand drug-diagnostic co-development is key.